HRP20090419T1 - Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli - Google Patents
Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli Download PDFInfo
- Publication number
- HRP20090419T1 HRP20090419T1 HR20090419T HRP20090419T HRP20090419T1 HR P20090419 T1 HRP20090419 T1 HR P20090419T1 HR 20090419 T HR20090419 T HR 20090419T HR P20090419 T HRP20090419 T HR P20090419T HR P20090419 T1 HRP20090419 T1 HR P20090419T1
- Authority
- HR
- Croatia
- Prior art keywords
- indeno
- indene
- thia
- aza
- dioxide
- Prior art date
Links
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 title 1
- QKDLQFSLLCQTOH-UHFFFAOYSA-N Trichodonin Natural products C1C(O)C2C3(COC(=O)C)C(C=O)C(C)(C)CCC3OC(=O)C22C(=O)C(=C)C1C2 QKDLQFSLLCQTOH-UHFFFAOYSA-N 0.000 title 1
- 150000002469 indenes Chemical class 0.000 title 1
- 150000002475 indoles Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 238000000034 method Methods 0.000 claims abstract 6
- 150000003839 salts Chemical class 0.000 claims abstract 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 208000015114 central nervous system disease Diseases 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- JJUQRPHMJPHFBH-UHFFFAOYSA-N 6h-isoindolo[2,1-a]indole Chemical class C1=CC=C2N3CC4=CC=CC=C4C3=CC2=C1 JJUQRPHMJPHFBH-UHFFFAOYSA-N 0.000 claims abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 208000030814 Eating disease Diseases 0.000 claims abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims abstract 2
- 208000002193 Pain Diseases 0.000 claims abstract 2
- 201000011529 cardiovascular cancer Diseases 0.000 claims abstract 2
- OZEPXROCWSMGGM-UHFFFAOYSA-N dibenzopentalene Chemical compound C1=CC=C2C=C3C4=CC=CC=C4C=C3C2=C1 OZEPXROCWSMGGM-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000014632 disordered eating Nutrition 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 208000014951 hematologic disease Diseases 0.000 claims abstract 2
- 208000023504 respiratory system disease Diseases 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 238000007363 ring formation reaction Methods 0.000 claims 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- KHUZRJFSVDHKPP-UHFFFAOYSA-N 11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CCC1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 KHUZRJFSVDHKPP-UHFFFAOYSA-N 0.000 claims 2
- KHUZRJFSVDHKPP-ZDUSSCGKSA-N 11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@@H]1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 KHUZRJFSVDHKPP-ZDUSSCGKSA-N 0.000 claims 2
- KHUZRJFSVDHKPP-CYBMUJFWSA-N 11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@H]1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 KHUZRJFSVDHKPP-CYBMUJFWSA-N 0.000 claims 2
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 2
- 206010033664 Panic attack Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- -1 monoalkylamino Chemical group 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- UYOMDXYLVLFRKM-UHFFFAOYSA-N 10-methoxy-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1=2C(OC)=CC=CC=2N(S(C2=CC=CC=C22)(=O)=O)C2=C1C1CCN(C)C1 UYOMDXYLVLFRKM-UHFFFAOYSA-N 0.000 claims 1
- UYOMDXYLVLFRKM-ZDUSSCGKSA-N 10-methoxy-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1=2C(OC)=CC=CC=2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@H]1CCN(C)C1 UYOMDXYLVLFRKM-ZDUSSCGKSA-N 0.000 claims 1
- UYOMDXYLVLFRKM-CYBMUJFWSA-N 10-methoxy-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1=2C(OC)=CC=CC=2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@@H]1CCN(C)C1 UYOMDXYLVLFRKM-CYBMUJFWSA-N 0.000 claims 1
- XZKJZIZCJBFPQW-UHFFFAOYSA-N 11-(1-ethylpyrrolidin-3-yl)-10-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CCC1C(C1=C(OC(C)C)C=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 XZKJZIZCJBFPQW-UHFFFAOYSA-N 0.000 claims 1
- LMVAVNDVYCWUHV-UHFFFAOYSA-N 11-(1-ethylpyrrolidin-3-yl)-9-methoxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CCC1C(C1=CC(OC)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 LMVAVNDVYCWUHV-UHFFFAOYSA-N 0.000 claims 1
- YJCSUJPPDKLDPZ-UHFFFAOYSA-N 11-(1-ethylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CCC1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 YJCSUJPPDKLDPZ-UHFFFAOYSA-N 0.000 claims 1
- LYPRLLGYUMVCCO-UHFFFAOYSA-N 11-(1-methylpyrrolidin-3-yl)-9-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC(C)C)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1C1CCN(C)C1 LYPRLLGYUMVCCO-UHFFFAOYSA-N 0.000 claims 1
- XZKJZIZCJBFPQW-INIZCTEOSA-N 11-[(3r)-1-ethylpyrrolidin-3-yl]-10-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@@H]1C(C1=C(OC(C)C)C=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 XZKJZIZCJBFPQW-INIZCTEOSA-N 0.000 claims 1
- LMVAVNDVYCWUHV-AWEZNQCLSA-N 11-[(3r)-1-ethylpyrrolidin-3-yl]-9-methoxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@@H]1C(C1=CC(OC)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 LMVAVNDVYCWUHV-AWEZNQCLSA-N 0.000 claims 1
- YJCSUJPPDKLDPZ-AWEZNQCLSA-N 11-[(3r)-1-ethylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@@H]1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 YJCSUJPPDKLDPZ-AWEZNQCLSA-N 0.000 claims 1
- LYPRLLGYUMVCCO-HNNXBMFYSA-N 11-[(3r)-1-methylpyrrolidin-3-yl]-9-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC(C)C)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@H]1CCN(C)C1 LYPRLLGYUMVCCO-HNNXBMFYSA-N 0.000 claims 1
- XZKJZIZCJBFPQW-MRXNPFEDSA-N 11-[(3s)-1-ethylpyrrolidin-3-yl]-10-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@H]1C(C1=C(OC(C)C)C=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 XZKJZIZCJBFPQW-MRXNPFEDSA-N 0.000 claims 1
- LMVAVNDVYCWUHV-CQSZACIVSA-N 11-[(3s)-1-ethylpyrrolidin-3-yl]-9-methoxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@H]1C(C1=CC(OC)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 LMVAVNDVYCWUHV-CQSZACIVSA-N 0.000 claims 1
- YJCSUJPPDKLDPZ-CQSZACIVSA-N 11-[(3s)-1-ethylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(CC)CC[C@H]1C(C1=CC=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 YJCSUJPPDKLDPZ-CQSZACIVSA-N 0.000 claims 1
- LYPRLLGYUMVCCO-OAHLLOKOSA-N 11-[(3s)-1-methylpyrrolidin-3-yl]-9-propan-2-yloxyindolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC(C)C)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@@H]1CCN(C)C1 LYPRLLGYUMVCCO-OAHLLOKOSA-N 0.000 claims 1
- NDVBCOKNZMKARJ-UHFFFAOYSA-N 2-methoxy-11-(1-methylpyrrolidin-3-yl)-6h-isoindolo[2,1-a]indole Chemical compound C12=CC(OC)=CC=C2N2CC3=CC=CC=C3C2=C1C1CCN(C)C1 NDVBCOKNZMKARJ-UHFFFAOYSA-N 0.000 claims 1
- NDVBCOKNZMKARJ-HNNXBMFYSA-N 2-methoxy-11-[(3r)-1-methylpyrrolidin-3-yl]-6h-isoindolo[2,1-a]indole Chemical compound C12=CC(OC)=CC=C2N2CC3=CC=CC=C3C2=C1[C@H]1CCN(C)C1 NDVBCOKNZMKARJ-HNNXBMFYSA-N 0.000 claims 1
- NDVBCOKNZMKARJ-OAHLLOKOSA-N 2-methoxy-11-[(3s)-1-methylpyrrolidin-3-yl]-6h-isoindolo[2,1-a]indole Chemical compound C12=CC(OC)=CC=C2N2CC3=CC=CC=C3C2=C1[C@@H]1CCN(C)C1 NDVBCOKNZMKARJ-OAHLLOKOSA-N 0.000 claims 1
- ZPEYHADPSYLBKI-UHFFFAOYSA-N 8-chloro-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CCC1C(C1=CC=C(Cl)C=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 ZPEYHADPSYLBKI-UHFFFAOYSA-N 0.000 claims 1
- ZPEYHADPSYLBKI-LBPRGKRZSA-N 8-chloro-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@@H]1C(C1=CC=C(Cl)C=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 ZPEYHADPSYLBKI-LBPRGKRZSA-N 0.000 claims 1
- ZPEYHADPSYLBKI-GFCCVEGCSA-N 8-chloro-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@H]1C(C1=CC=C(Cl)C=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 ZPEYHADPSYLBKI-GFCCVEGCSA-N 0.000 claims 1
- CVTNYIIMXSBKFO-UHFFFAOYSA-N 8-methoxy-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C=12C3=CC=CC=C3S(=O)(=O)N2C2=CC(OC)=CC=C2C=1C1CCN(C)C1 CVTNYIIMXSBKFO-UHFFFAOYSA-N 0.000 claims 1
- CVTNYIIMXSBKFO-ZDUSSCGKSA-N 8-methoxy-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C=12C3=CC=CC=C3S(=O)(=O)N2C2=CC(OC)=CC=C2C=1[C@H]1CCN(C)C1 CVTNYIIMXSBKFO-ZDUSSCGKSA-N 0.000 claims 1
- CVTNYIIMXSBKFO-CYBMUJFWSA-N 8-methoxy-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C=12C3=CC=CC=C3S(=O)(=O)N2C2=CC(OC)=CC=C2C=1[C@@H]1CCN(C)C1 CVTNYIIMXSBKFO-CYBMUJFWSA-N 0.000 claims 1
- HUFKRJSZPYMMOP-UHFFFAOYSA-N 9-cyclopentyloxy-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CCC1C(C1=CC(OC2CCCC2)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 HUFKRJSZPYMMOP-UHFFFAOYSA-N 0.000 claims 1
- HUFKRJSZPYMMOP-INIZCTEOSA-N 9-cyclopentyloxy-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@@H]1C(C1=CC(OC2CCCC2)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 HUFKRJSZPYMMOP-INIZCTEOSA-N 0.000 claims 1
- HUFKRJSZPYMMOP-MRXNPFEDSA-N 9-cyclopentyloxy-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C1N(C)CC[C@H]1C(C1=CC(OC2CCCC2)=CC=C11)=C2N1S(=O)(=O)C1=CC=CC=C12 HUFKRJSZPYMMOP-MRXNPFEDSA-N 0.000 claims 1
- YTMUEYSZWSRFEN-UHFFFAOYSA-N 9-ethoxy-11-(1-ethylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1C1CCN(CC)C1 YTMUEYSZWSRFEN-UHFFFAOYSA-N 0.000 claims 1
- AGZZATBAXFXGGX-UHFFFAOYSA-N 9-ethoxy-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1C1CCN(C)C1 AGZZATBAXFXGGX-UHFFFAOYSA-N 0.000 claims 1
- YTMUEYSZWSRFEN-HNNXBMFYSA-N 9-ethoxy-11-[(3r)-1-ethylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@H]1CCN(CC)C1 YTMUEYSZWSRFEN-HNNXBMFYSA-N 0.000 claims 1
- AGZZATBAXFXGGX-AWEZNQCLSA-N 9-ethoxy-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@H]1CCN(C)C1 AGZZATBAXFXGGX-AWEZNQCLSA-N 0.000 claims 1
- YTMUEYSZWSRFEN-OAHLLOKOSA-N 9-ethoxy-11-[(3s)-1-ethylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@@H]1CCN(CC)C1 YTMUEYSZWSRFEN-OAHLLOKOSA-N 0.000 claims 1
- AGZZATBAXFXGGX-CQSZACIVSA-N 9-ethoxy-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OCC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@@H]1CCN(C)C1 AGZZATBAXFXGGX-CQSZACIVSA-N 0.000 claims 1
- PSZOQNKYJSTJNP-UHFFFAOYSA-N 9-methoxy-11-(1-methylpyrrolidin-3-yl)indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1C1CCN(C)C1 PSZOQNKYJSTJNP-UHFFFAOYSA-N 0.000 claims 1
- PSZOQNKYJSTJNP-ZDUSSCGKSA-N 9-methoxy-11-[(3r)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@H]1CCN(C)C1 PSZOQNKYJSTJNP-ZDUSSCGKSA-N 0.000 claims 1
- PSZOQNKYJSTJNP-CYBMUJFWSA-N 9-methoxy-11-[(3s)-1-methylpyrrolidin-3-yl]indolo[1,2-b][1,2]benzothiazole 5,5-dioxide Chemical compound C12=CC(OC)=CC=C2N(S(C2=CC=CC=C22)(=O)=O)C2=C1[C@@H]1CCN(C)C1 PSZOQNKYJSTJNP-CYBMUJFWSA-N 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010027603 Migraine headaches Diseases 0.000 claims 1
- 208000018526 Narcotic-Related disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000003280 chronobiological effect Effects 0.000 claims 1
- 230000027288 circadian rhythm Effects 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004756 ethanol Drugs 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000003906 hydrocephalus Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 208000030212 nutrition disease Diseases 0.000 claims 1
- 229910052763 palladium Inorganic materials 0.000 claims 1
- WXHIJDCHNDBCNY-UHFFFAOYSA-N palladium dihydride Chemical class [PdH2] WXHIJDCHNDBCNY-UHFFFAOYSA-N 0.000 claims 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical group [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 208000014001 urinary system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN5CH2004 | 2004-01-02 | ||
| PCT/IN2004/000430 WO2005066184A1 (en) | 2004-01-02 | 2004-12-30 | Novel indeno[2,1a]indenes and isoindol[2,1-a]indoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090419T1 true HRP20090419T1 (hr) | 2009-09-30 |
Family
ID=34746651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090419T HRP20090419T1 (hr) | 2004-01-02 | 2009-07-29 | Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7388024B2 (no) |
| EP (1) | EP1704154B1 (no) |
| JP (1) | JP4886522B2 (no) |
| KR (1) | KR101049868B1 (no) |
| CN (1) | CN1918173B (no) |
| AT (1) | ATE430752T1 (no) |
| AU (1) | AU2004312229B2 (no) |
| BR (1) | BRPI0417895B8 (no) |
| CA (1) | CA2552106C (no) |
| CY (1) | CY1109278T1 (no) |
| DE (1) | DE602004021031D1 (no) |
| DK (1) | DK1704154T3 (no) |
| EA (1) | EA010406B1 (no) |
| ES (1) | ES2326658T3 (no) |
| HK (1) | HK1097548A1 (no) |
| HR (1) | HRP20090419T1 (no) |
| MX (1) | MXPA06007415A (no) |
| NO (1) | NO335838B1 (no) |
| NZ (1) | NZ548743A (no) |
| PL (1) | PL1704154T3 (no) |
| PT (1) | PT1704154E (no) |
| RS (1) | RS50824B (no) |
| SI (1) | SI1704154T1 (no) |
| WO (1) | WO2005066184A1 (no) |
| ZA (1) | ZA200604748B (no) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102482292B (zh) * | 2009-04-23 | 2017-07-18 | Abbvie 公司 | 5‑ht受体的调节剂和其使用方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994352A (en) * | 1998-11-13 | 1999-11-30 | Pfizer Inc. | 5-arylindole derivatives |
| ATE368658T1 (de) * | 2000-12-22 | 2007-08-15 | Wyeth Corp | Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden |
| DE60214990T2 (de) * | 2001-01-30 | 2007-04-05 | Eli Lilly And Co., Indianapolis | Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten |
| PT1438045E (pt) | 2001-10-23 | 2007-05-31 | Biovitrum Ab | Utilização de derivados de indole e indolina para o tratamento da obesidade ou para a redução de ingestão de alimentos |
| ES2187300B1 (es) * | 2001-11-14 | 2004-06-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. |
| BR0215222A (pt) * | 2001-12-20 | 2005-05-24 | Wyeth Corp | Derivados de indolilalquilamina como ligantes de 5-hidroxitriptamina-6 |
| US20050255529A1 (en) | 2002-02-01 | 2005-11-17 | Stefan Golz | Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| US20070270432A1 (en) | 2002-02-05 | 2007-11-22 | James Hagan | Novel Method |
| RU2320663C2 (ru) * | 2002-06-21 | 2008-03-27 | Сувен Лайф Сайенсиз Лимитед | Новые арилалкилиндолы с аффинностью к серотониновым рецепторам, пригодные в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции |
| AU2003249583B2 (en) * | 2002-06-21 | 2007-06-07 | Suven Life Sciences Limited | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| CA2490254C (en) * | 2002-06-21 | 2011-11-01 | Suven Life Sciences Limited | Novel tetracyclic arylsulfonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them |
| AU2003292508A1 (en) | 2002-11-28 | 2004-06-18 | Suven Life Sciences Limited | N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands |
| BRPI0315959C1 (pt) | 2002-11-28 | 2021-05-25 | Suven Life Sciences Ltd | composto, composição farmacêutica, uso do composto, método para o tratamento, método para reduzir a morbidez e a mortalidade associadas com o excesso de peso e processo para a preparação do composto |
| ES2425143T3 (es) | 2002-11-28 | 2013-10-11 | Suven Life Sciences Limited | N-Arilsulfonil-3-aminoalcoxiindoles |
| NZ540841A (en) | 2002-12-18 | 2008-08-29 | Suven Life Sciences Ltd | Tetracyclic 3-substituted indoles having serotonin receptor affinity |
-
2004
- 2004-12-30 AU AU2004312229A patent/AU2004312229B2/en not_active Ceased
- 2004-12-30 MX MXPA06007415A patent/MXPA06007415A/es active IP Right Grant
- 2004-12-30 PL PL04806777T patent/PL1704154T3/pl unknown
- 2004-12-30 AT AT04806777T patent/ATE430752T1/de active
- 2004-12-30 EA EA200601270A patent/EA010406B1/ru not_active IP Right Cessation
- 2004-12-30 DK DK04806777T patent/DK1704154T3/da active
- 2004-12-30 PT PT04806777T patent/PT1704154E/pt unknown
- 2004-12-30 BR BRPI0417895A patent/BRPI0417895B8/pt not_active IP Right Cessation
- 2004-12-30 CN CN2004800417654A patent/CN1918173B/zh not_active Expired - Fee Related
- 2004-12-30 KR KR1020067012980A patent/KR101049868B1/ko active IP Right Grant
- 2004-12-30 JP JP2006546485A patent/JP4886522B2/ja not_active Expired - Fee Related
- 2004-12-30 ES ES04806777T patent/ES2326658T3/es active Active
- 2004-12-30 RS RSP-2009/0329A patent/RS50824B/sr unknown
- 2004-12-30 DE DE602004021031T patent/DE602004021031D1/de active Active
- 2004-12-30 WO PCT/IN2004/000430 patent/WO2005066184A1/en active Application Filing
- 2004-12-30 CA CA2552106A patent/CA2552106C/en not_active Expired - Fee Related
- 2004-12-30 NZ NZ548743A patent/NZ548743A/xx not_active IP Right Cessation
- 2004-12-30 EP EP04806777A patent/EP1704154B1/en active Active
- 2004-12-30 SI SI200431175T patent/SI1704154T1/sl unknown
-
2006
- 2006-06-09 ZA ZA200604748A patent/ZA200604748B/xx unknown
- 2006-06-15 NO NO20062805A patent/NO335838B1/no not_active IP Right Cessation
- 2006-06-29 US US11/478,968 patent/US7388024B2/en active Active
-
2007
- 2007-05-14 HK HK07105039.5A patent/HK1097548A1/xx not_active IP Right Cessation
-
2009
- 2009-07-29 HR HR20090419T patent/HRP20090419T1/hr unknown
- 2009-08-03 CY CY20091100812T patent/CY1109278T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2940319T3 (es) | Separación enantiomérica de nicotina racémica mediante la adición de un enantiómero de ácido tartárico O,O'-disustituido de baja pureza óptica | |
| RU2372350C2 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ 2-(1-АЗА-БИЦИКЛО[2.2.2]ОКТ-3-ИЛ)-2,3-ДИГИДРОИЗОИНДОЛ-1-ОНА/5,6-ДИГИДРО-ФУРО[2,3-c]ПИРРОЛ-4-ОНА В КАЧЕСТВЕ ЛИГАНДОВ К АЛЬФА 7 НИКОТИНОВОМУ АЦЕТИЛХОЛИНОВОМУ РЕЦЕПТОРУ | |
| RU2005104434A (ru) | Производные 1-гетероциклилалкил-3-сульфонилиндола или - индазола как лиганды 5-гидрокситриптамина-6 | |
| IS6459A (is) | Arýl sambrædd azapólýsýklísk efnasambönd | |
| TW200505907A (en) | Piperidine-benzenesulfonamide derivatives | |
| RU2010119554A (ru) | Замещенные n-фенил-бипирролидинмочевины и их терапевтическое применение | |
| AR062907A1 (es) | Derivados de sulfonilpirazol y sulfonilpirazolincarboxamidina como antagonistas de 5-ht6 | |
| TW200630371A (en) | Halogen substituted benzodiazepine derivatives | |
| US20030232853A1 (en) | Azabicyclic compounds for the treatment of disease | |
| TW200630372A (en) | Imidazo-benzodiazepine derivatives | |
| ATE428694T1 (de) | N-ä1h-indol-5-ylünaphthalin-1-sulphonamid- derivate und verwandte verbindungen als serotonin 5-ht6 rezeptor antagonisten zur behandlung von erkrankungen des zentralen nervensystems | |
| MX2007004250A (es) | Derivados de imidazo[1,5-a]triazolo[1,5-d]benzodiazepina para el tratamiento de trastornos cognitivos. | |
| CA2113603C (en) | Tricyclic condensed heterocyclic compounds, their production and use | |
| BR0013498A (pt) | Composto, método para a preparação do mesmo, composição farmacêutica, e, métodos para a preparação da mesma e para o tratamento de distúrbios do snc | |
| ATE401072T1 (de) | 1-arylsulfonyl-3-substituierte indol und indolinederivate verwendbar zur behandlung von erkrankungen des zentralnervensystem | |
| RU2004122129A (ru) | Производные индолилалкиламина в качестве лтгандов 5-гидрокситриптамина-6 | |
| ATE271553T1 (de) | Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| JP2006519868A5 (no) | ||
| HRP20100604T1 (hr) | Derivati 4h-1,2,4-triazin-5-ona, njihova priprava i njihova uporaba kao alfa 7 nikotinskih acetilkolinskih receptora | |
| CA2354606A1 (en) | Azabicycloalkane derivatives and therapeutic uses thereof | |
| CA2507923A1 (en) | Tetracyclic 3-substituted indoles having serotonin receptor affinity | |
| HRP20090419T1 (hr) | Novi indeno[2,1a]indeni i izoindol[2,1-a]indoli | |
| DE69222444T2 (de) | Substituierte 1,2,3,4-Tetrahydrocyclopent[b]indole, 1,2,3,3a,4,8a-Hexahydrocyclopent[b]indole und verwandte Verbindungen, Zwischenprodukte und ein Verfahren zur Herstellung derselben und ihre Verwendung als Medikamente | |
| RU2007125691A (ru) | Бенздиоксановые производные пиперазина с комбинацией сродства к допаминовым-d2 рецепторам и участкам обратного захвата серотонина |